Press

The FTD Disorders Registry in collaboration with the Association for Frontotemporal Degeneration (AFTD) published its first full-length, peer-reviewed journal article in 2022.

Of the 817 responses to our Quick Question, nearly half (400) indicated that the FTD-diagnosed person lives or lived with their spouse and children …

The FTD Disorders Registry received the 2022 MarDreamies Award for Grassroots Innovation for its use of technology to collect data from participants …

CurePSP is hosting a Community Conversations webinar about “The Powerful Role of Grandchildren Caring for PSP, CBD, and MSA” on Thursday, February 2

The age range most reported for when the first frontotemporal degeneration (FTD) symptom appeared was between 55 and 59 years (158 people)

Travis Turner, PhD, will discuss Assessing Cognitive Changes with PSP, CBD, and MSA during a CurePSP Ask the Expert webinar on Monday, Dec.

Learn about management techniques for PSP, CBD, and MSA during the CurePSP’s Virtual Fall Family Conference on two Fridays December 9th and 16th. Each day will feature different speakers who will present on different topics.

The age range that most people received a diagnosis of frontotemporal degeneration (FTD) was between 60 and 64 years (182 people), according to…

Perspectives in FTD Research Webinar Series

A clinical trial seeking a disease-modifying therapy for people with svPPA A new clinical trial that is testing a known drug hopes to slow the progression of semantic variant primary progressive aphasia (svPPA). It will test the effects of verdiperstat on cerebrospinal fluid (CSF) proteins, brain magnetic resonance imaging (MRI), and cognitive tests. A Trial of Verdiperstat in Patients With svPPA…